Dafna Capital Management LLC Compugen LTD Transaction History

Dafna Capital Management LLC

$368 Million
Q4 2024

A detailed history of Dafna Capital Management LLC transactions in Compugen LTD stock. As of the latest transaction made, Dafna Capital Management LLC holds 447,202 shares of CGEN stock, worth $858,627. This represents 0.19% of its overall portfolio holdings.

Number of Shares

447,202

Previous 447,202 -0.0%

Holding current value

$858,627

Previous $809,000 15.45%

% of portfolio

0.19%

Previous 0.21%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.56 - $2.1 $23,400 - $31,500	-15,000 Reduced 3.25%	447,202 $809,000
Q2 2024 Aug 14, 2024	BUY	$1.68 - $2.52 $53,760 - $80,640	32,000 Added 7.44%	462,202 $776,000
Q1 2024 May 15, 2024	BUY	$1.75 - $2.95 $393,750 - $663,750	225,000 Added 109.65%	430,202 $1.11 Million
Q2 2022 Aug 15, 2022	BUY	$1.57 - $3.33 $117,750 - $249,750	75,000 Added 57.6%	205,202 $380,000
Q1 2022 May 16, 2022	SELL	$2.76 - $4.64 $196,787 - $330,832	-71,300 Reduced 35.38%	130,202 $419,000
Q2 2021 Aug 16, 2021	BUY	$6.87 - $9.16 $85,875 - $114,500	12,500 Added 6.61%	201,502 $1.67 Million
Q1 2021 May 17, 2021	BUY	$7.67 - $13.77 $566,046 - $1.02 Million	73,800 Added 64.06%	189,002 $1.62 Million
Q3 2020 Nov 16, 2020	SELL	$14.16 - $19.45 $3.23 Million - $4.43 Million	-227,844 Reduced 66.42%	115,202 $1.87 Million
Q2 2020 Aug 14, 2020	SELL	$6.97 - $17.12 $1.79 Million - $4.4 Million	-256,954 Reduced 42.83%	343,046 $5.15 Million
Q1 2020 May 15, 2020	BUY	$5.79 - $11.83 $3.47 Million - $7.1 Million	600,000 New	600,000 $4.36 Million

Others Institutions Holding CGEN

# of Institutions

Shares Held

13.4M

Call Options Held

44.9K

Put Options Held

8.1K

View Full List

About COMPUGEN LTD

Ticker CGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,600
Market Cap $166M
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...

More about CGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dafna Capital Management LLC with notifications on news.

Account

Dafna Capital Management LLC Compugen LTD Transaction History